These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8562266)

  • 1. [The treatment of hypercholesterolemia in primary and secondary prevention].
    Sirtori CR
    Ann Ital Med Int; 1995 Oct; 10 Suppl():48S-52S. PubMed ID: 8562266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
    Thorvik E; Aursnes I; Kristiansen IS; Waaler HT
    Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
    Szucs TD; Gutzwiller F
    Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacoeconomic benefits of cholesterol reduction.
    Gonzalez ER
    Am J Manag Care; 1998 Feb; 4(2):223-30. PubMed ID: 10178493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies in primary prevention among hyperlipidemic patients.
    McPherson R
    Can J Cardiol; 1999 Apr; 15 Suppl B():16B-19B. PubMed ID: 10350678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and cost among lipid-lowering agents in patients with primary hypercholesterolemia.
    Lacour A; Derderian F; LeLorier J
    Can J Cardiol; 1998 Mar; 14(3):355-61. PubMed ID: 9551029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of prescription recommendations for cholesterol-lowering drugs: a survey of a representative sample of American cardiologists.
    Gaspoz JM; Kennedy JW; Orav EJ; Goldman L
    J Am Coll Cardiol; 1996 Apr; 27(5):1232-7. PubMed ID: 8609348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological treatment of lipid disorders according to present clinical studies].
    Bańcarz A; Jołda-Mydłowska B; Swidnicka-Szuszkowska B
    Pol Merkur Lekarski; 1998 Sep; 5(27):162-6. PubMed ID: 10101487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E; Harats D; Gavish D
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
    Marchioli R; Marfisi RM; Carinci F; Tognoni G
    Arch Intern Med; 1996 Jun; 156(11):1158-72. PubMed ID: 8639010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.
    Montagne O; Vedel I; Durand-Zaleski I
    Clin Ther; 1999 Nov; 21(11):2027-35. PubMed ID: 10890271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A survey on the status of lipid-lowering therapy in 180 hypercholesterolemic patients].
    Cai S; Xia S; Xie H; Yao X; Wang L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Oct; 23(5):378-81; discussion 381-2. PubMed ID: 12482372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
    Kostner KM; Kostner GM
    Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of cholesterol-lowering drugs in prevention of coronary heart disease].
    Skałuba Z; Undas R
    Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.